The role of Nrf2 in protecting AML cells from chemotherapy-induced apotosis

Bowles, Kristian (Principal Investigator)
Rushworth, Stuart (Co-Investigator)

Status	Finished
Effective start/end date	1/04/12 → 31/03/15

Funding

Association for International Cancer Research: £193,106.00

Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells
Rushworth, S. A., Pillinger, G., Abdul-Aziz, A., Piddock, R., Shafat, M. S., Murray, M. Y., Zaitseva, L., Lawes, M. J., MacEwan, D. J. & Bowles, K. M., 1 May 2015, In: The Lancet Haematology. 2, 5, p. e204-e211 8 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File

26 Citations (Scopus)

23 Downloads (Pure)
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML
Zaitseva, L., Murray, M. Y., Shafat, M. S., Lawes, M. J., MacEwan, D. J., Bowles, K. M. & Rushworth, S. A., 30 Oct 2014, In: Oncotarget. 5, 20, p. 9930-9938 9 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File

66 Citations (Scopus)

37 Downloads (Pure)